The role of budget impact in reimbursement decisions in The Netherlands: interviews with decision-makers and pharmaceutical industry representatives.

ABSTRACT: Economic evaluations of health technologies increasingly encompass a cost-effectiveness analysis (CEA) and a supplementary budget impact analysis (BIA) to inform reimbursement decisions on health technologies. Evidence from the Netherlands suggests that CEA requirements are consistent between the different stages of the decision-making process in the Netherlands, while BIA requirements are not. It remains unclear why aspects of BIAs vary in form and importance across decision stages, and why BIA results do not have a clear and consistent relationship with CEA results. Therefore, this study aimed to obtain further insight into the role of budget impact in the different stages of the decision-making process in the Netherlands, and into the experiences of decision-makers that may explain the

SUBMITTER: Reckers-Droog V 

PROVIDER: S-EPMC12572102 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature